Data / Form D filings / Adaptimmune Ltd
Adaptimmune Ltd: Form D filing
Adaptimmune Ltd, a biotechnology company in Abingdon, Oxfordshire, United Kingdom, filed a Form D with the SEC in 2014. The latest, on October 2, 2014, reports $103.8 million sold of a $103.8 million offering to 22 investors.
Find out what Adaptimmune Ltd does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 91 PARK DRIVE, MILTON PARK, Abingdon, Oxfordshire, United Kingdom, OX14
- Phone
- 44 1235 430000
- Industry
- Biotechnology
- Entity type
- Other (Private Limited Company)
- Incorporated in
- United Kingdom
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1621227
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2014 | New notice | $103,809,789 | $103,809,789 | $0 | 22 | Sep 23, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| David Mott | Director | |
| Ali Behbahani | Director | |
| Peter Thompson | Director | |
| Elliott Sigal | Director | |
| Dr. Jonathan Knowles | Director | |
| James Noble | Executive Officer, Director | |
| Ian Laing | Director |
Every Form D from the week of Sep 29, 2014 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Adaptimmune Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.